Malaria Parasite Killed By Bone Medication

Recommend to others!

A chemically changed osteoporosis medicine might be helpful in fighting malaria, investigators report in a novel research. Unlike other similar compounds that were tested against other parasitic protozoa, this medicine immediately crossed into the RBC of the mice which were infected with malaria and killed the malaria parasite. The medicine worked at low concentration and did not result in any toxicity in mouse.  The researchers discovered the medicine while they were viewing a library that had 1000 compounds which were earlier used to aim an imperative biochemical pathway in cancer.

The novel medicine BPH 703 slows down a main enzyme which allows the malaria parasite to hold itself and protect itself against the host immune system. This medicine has little impact on the similar chemical pathway in mouse or human cells. The lead composite are altered chemically from bone medicines and they potently obstruct isoprenoid biosynthesis, but they are not capable of getting through the membrane of RBC to get the parasite. This altered medicine included a long lipid tail which helped them get across the membrane of RBC which is rich in lipid. This also enhanced the ability of the medicine to hold the main enzyme.

The researchers also established that compounds were very active and had a very lengthy hydrocarbon chain. These compounds have the ability to get through the cell membrane and function at very low concentration. It is very important to discover a novel medicine target since the malaria medicines work only for few years and then the individuals start getting resistant. The malaria parasites transform and then the individuals lose the malaria medicine.  The researchers prove that they are the first ones to demonstrate that the GGPPS enzyme is the most appropriate target for malaria. Their work will open new doors to discover novel anti-malaria medicines.



Speak Your Mind


Current day month ye@r *